Study of how teclistamab works in multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks closely at patients’ immune cells to understand why teclistamab helps in multiple myeloma. Your participation could help doctors better predict who benefits and how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma.
- You are receiving (or will receive) teclistamab as part of your care.
- You can sign a consent form to take part in the study.
- You are not under “legal protection” (a legal status that limits certain permissions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well teclistamab works for people with multiple myeloma that has come back or not responded to at least three prior treatments. You may be eligible if you are starting teclistamab as part of your regular care.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.